Effect of the oral hypoglycaemic sulphonylurea glibenclamide, a blocker of ATP-sensitive potassium channels, on walking distance in patients with intermittent claudication
| Autor: | Jens Erik Nielsen-Kudsk, Ulrik Markus Mortensen, P. Jakobsen, Ole Schmitz, Hanne Maare Søndergaard, T.T. Nielsen, B. S. Jensen |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Blood Glucose
Male medicine.medical_specialty ATP-sensitive potassium channel Endocrinology Diabetes and Metabolism medicine.medical_treatment Administration Oral Pain Blood Pressure Walking Placebo Glibenclamide Endocrinology Adenosine Triphosphate Double-Blind Method Oral administration Internal medicine Glyburide Internal Medicine medicine Potassium Channel Blockers Humans Hypoglycemic Agents Insulin Serum Albumin Aged Cross-Over Studies business.industry Intermittent Claudication Middle Aged Crossover study Intermittent claudication Anesthesia Exercise Test Potassium Female medicine.symptom business Claudication medicine.drug |
| Zdroj: | Diabetic medicine : a journal of the British Diabetic Association. 23(3) |
| ISSN: | 0742-3071 |
| Popis: | Aims The oral hypoglycaemic sulphonylurea glibenclamide stimulates endogenous insulin secretion through blockade of ATP-sensitive potassium (KATP) channels on pancreatic β cells, but also blocks cardiovascular KATP channels, leading to increased peripheral vascular resistance and reduced peripheral blood flow in non-diabetic subjects. Therefore, this study examined whether a single oral dose of glibenclamide adversely affected the pain-free or maximal walking distance in patients with intermittent claudication. Methods In a double-blind, randomized crossover study, 12 non-diabetic patients with intermittent claudication were given a single oral dose of glibenclamide (5.25 mg) or placebo separated by a washout period of 1 week. A treadmill test was carried out 180 min after glibenclamide/placebo intake for determination of pain-free and maximal walking distance. Plasma glucose concentrations were kept constant by an euglycemic clamp. Changes in ankle/brachial blood pressure index (ABI), serum insulin, and serum glibenclamide were also assessed. Results The pain-free walking distance was 62.8 ± 9.8 metres (mean ± sem) after glibenclamide and 52.6 ± 5.9 metres after placebo (P = 0.52). The maximal walking distance was 142.7 ± 18.7 metres after glibenclamide and 132.6 ± 16.6 metres after placebo (P = 0.23). The ABI was not significantly changed by glibenclamide compared with placebo. Serum glibenclamide was 0.51 ± 0.08 µm 180 min after administration of the drug. Glibenclamide produced an 8-fold increase in circulating insulin compared with placebo (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text